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Quadriceps muscle strength in scoliosis
E.B. Swallow*, E. Barreiro#, H. Gosker", S.A. Sathyapala*, F. Sanchez#,
N.S. Hopkinson*, J. Moxham+, A. Schols", J. Gea# and M.I. Polkey*, on behalf of the
ENIGMA in COPD project
ABSTRACT: Quadriceps muscle weakness is an important component of chronic obstructive
pulmonary disease (COPD). We hypothesised that quadriceps weakness would also be a feature
of restrictive lung disease due to scoliosis.
We studied 10 patients with severe scoliosis (median (interquartile range (IQR)) forced
expiratory volume in 1 s (FEV1) 35.3 (11)% predicted), 10 patients with severe COPD (FEV1 26.5
(9.0)% pred) and 10 healthy age-matched adults. We measured quadriceps strength, exercise
capacity and analysed quadriceps muscle biopsies for myosin heavy-chain (MyHC) isoform
expression and the presence of oxidative stress.
Both groups exhibited quadriceps weakness with median (IQR) maximal voluntary contraction
force being 46.0 (17.0) kg, 21.5 (21.0) kg and 31.5 (11.0) kg, respectively (p50.02 and 0.04,
respectively, for each patient group against controls). Oxidative stress was significantly greater in
the quadriceps of both restrictive and COPD patients. The scoliosis patients exhibited a decrease
in the proportion of MyHC type I compared with controls; median (IQR) 35.3 (18.5)% compared
with 47.7 (9.3)%, p50.028. The scoliosis patients also showed an increase in MyHC IIx (26.3
(15.5)% compared with 11.3 (13.0)%, p50.01.
Quadriceps weakness is a feature of severe scoliosis; the similarities between patients with
scoliosis and patients with COPD suggest a common aetiology to quadriceps weakness in both
conditions.
KEYWORDS: Chronic obstructive pulmonary disease, extrapulmonary restrictive lung disease,
oxidative stress, quadriceps muscle weakness
I
n patients with advanced chronic obstructive
pulmonary disease (COPD), quadriceps
wasting and weakness are both features
which suggest a poor prognosis [1, 2], but few
data exist concerning quadriceps weakness in
other chronic pulmonary diseases and, to our
knowledge, none on the underlying muscle
phenotype and molecular changes. Although
pulmonary rehabilitation (PR) is of benefit in
both patients with restrictive lung disease [3] and
COPD [4], most investigators agree that precise
understanding of the causes of quadriceps
weakness in pulmonary disease might allow the
development of therapies that could be offered to
patients as an adjunct to PR or to patients who
are unable to participate in PR.
In addition to weakness, several biopsy-based
observations are recognised as components of the
COPD quadriceps phenotype. These include
oxidative stress [5] along with a fibre type switch
to a less resistant phenotype [6]. Since scoliosis,
like COPD, when severe causes exercise limitation
and respiratory failure, we considered that we
might also observe quadriceps weakness in
patients with scoliosis and that they might exhibit
a peripheral muscle phenotype which resembled
that of patients with COPD.
METHODS
Subjects
10 patients with idiopathic scoliosis and 10 patients
with severe COPD were recruited from the home
ventilation and advanced emphysema clinics at the
Royal Brompton Hospital (Imperial College,
London, UK). The scoliotic patients had been
referred for assessment of symptoms that might
be attributable to nocturnal hypoventilation in the
presence of reduced spirometry. COPD patients
had been referred for this purpose or for considera-
tion of lung volume reduction surgery or lung
transplantation. Subjects were stable at the time of
the study and were on standard treatment for their
lung disease, including, where appropriate,
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bronchodilators and inhaled corticosteroids, but not noninvasive
ventilation, which was the reason for referral. No patients were
on long-term oral steroids. Two of the COPD patients had
received short courses of oral prednisolone as treatment for
exacerbation: most recently, one patient had received predniso-
lone 4 months and the other 5 months prior to being studied.
Exclusion criteria included cardiovascular disease, chronic
metabolic diseases, suspected para-neoplastic or myopathic
syndromes, and/or treatment with drugs known to alter muscle
structure and/or function. Five patients in the COPD group were
on long-term domiciliary oxygen as opposed to one in the
scoliosis group. 10 healthy age-matched control subjects recruited
from a register in our laboratory were also studied. The Royal
Brompton Hospital Research Ethics Committee approved the
study and all subjects provided written, informed consent.
Nutritional and physiological measurements
Anthropometric measurements, fat-free mass determined by
bioelectrical impedance analysis [7] and pulmonary function
tests were recorded in both patients and controls. Patients in
the restrictive group had their arm span distance used instead
of height since it was greater [8]. The patient groups also
completed a 6-min walk test (6MWT) repeated on two
occasions; the highest result obtained was used for analysis.
Quadriceps force measurements
Subjects were studied supine, with the knee flexed at 90u over
the end of the bed, in a modification of the method of EDWARDS
et al. [9]; the dominant leg was studied and signals recorded
using apparatus previously described [10]. Quadriceps
strength was measured by supramaximal magnetic stimulation
of the femoral nerve (quadriceps twitch force (TwQ)) and by
maximal isometric voluntary contraction (quadriceps maximal
voluntary contraction (QMVC)) following a 20-min rest period
for depotentiation [11]. Femoral nerve stimulation [12] was
performed with a double Magstim 200 magnetic stimulator
(Magstim Co., Dyfed, UK) discharging both units simulta-
neously through a 70-mm ‘‘branding iron’’ coil. The optimal
coil position was determined at the start of the experiment;
supramaximality was confirmed in each subject by recording
the unpotentiated TwQ at a range of stimulus intensities
between 70 and 100% output. A minimum of seven stimuli at
100% were then performed and TwQ defined as the mean of
these recordings. QMVC was performed so that the force
generated was visible to subject and investigator for positive
feedback. Efforts were sustained for o5 s. Subjects rested for
30 s between each contraction to minimise ‘‘twitch-on-twitch’’
potentiation [13]. A minimum of three efforts was made with
vigorous encouragement until there was no improvement in
performance; the biggest effort recorded was used for analysis.
Quadriceps muscle biopsy
A needle biopsy of the vastus lateralis of the contralateral (i.e.
non-dominant) leg was performed in all subjects [14]. The
samples were immediately frozen in liquid nitrogen and stored
at -80uC until further processing.
Muscle biopsy analyses
Full details may be found in the supplementary material
available online but, in brief, we performed analysis for
myosin heavy-chain (MyHC) isoform expression at the
University of Maastricht (Maastricht, the Netherlands) using
previously described methods [15]. We also sought evidence of
oxidative stress in muscle proteins and lipids in Barcelona
using previously described methods [5, 16, 17].
Statistical analysis
Data are expressed as median¡interquartile range unless
otherwise stated. Differences between the three groups were
explored using the Kruskal–Wallis test followed by the Mann–
Whitney test since it could not be safely assumed that the data
were normally distributed. A p-value of ,0.05 was taken to be
significant. A statistical software package was used for all
calculations (Statview; SAS Institute, Cary, NC, USA).
RESULTS
Characteristics of the study subjects
The characteristics of the subjects are shown in table 1. The
patient and control groups were well matched with respect to
age. Fat-free mass index did not differ between groups but the
body mass index (BMI) was reduced in scoliotic patients
compared with both controls and COPD patients (p50.03 for
both). There was significant but comparable lung function
abnormality, judged by forced expiratory volume in 1 s (FEV1),
in both patient groups with a median (IQR) FEV1 of 35.3 (11)%
predicted for the scoliotic patients and a severe obstructive
defect in the COPD group (FEV1 26.5 (9.0)% pred).







Subjects n 10 10 10
Males n 10 3 10
Age yrs 61 (13) 63.5 (6.0) 65.0 (13.0)
Height/arm span m 1.76 (0.9) 1.62 (0.34)*,# 1.75 (0.6)
Weight kg 81.1 (13.8) 57.9 (27.7)*,# 86.3 (24.4)
BMI kg?m-2 26.0 (4.0) 22.4 (9.1)*,# 27.6 (5.9)
FFMI kg?m-2 18.0(2.3) 14.9 (7.5) 17.7 (1.9)
FEV1 % pred 89.5 (33.0) 35.3 (11.0)* 26.5 (9.0)*
FVC % pred 90.0 (20.0) 44.0 (22.0)* 73.0 (20.0)*
FEV1/FVC 83.0 (15.0) 80.1 (15.2) 31.4 (16.6)*
Pa,O2 kPa 9.1 (1.13) 7.49 (1.71)
Pa,CO2 kPa 5.73 (1.29) 6.64 (0.88)
6MWD m 300 (199) 155 (180)
QMVC kg 46.0 (17.0) 21.5 (21.0)* 31.5 (11.0)*
QMVC as % of BMI 172 (48.4) 106 (33.0)* 115 (21.1)*
TwQ kg 9.65 (3.0) 5.9 (3.3)* 6.5 (4.3)
Data are presented as median (interquartile range), unless otherwise stated.
COPD: chronic obstructive pulmonary disease; BMI: body mass index; FFMI:
fat-free mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted;
FVC: functional vital capacity; Pa,O2: arterial oxygen tension; Pa,CO2: arterial
carbon dioxide tension; 6MWD: 6-min walk distance; QMVC: quadriceps
maximal voluntary contraction; TwQ: quadriceps twitch force. *: p,0.05 or
smaller between patient group and control group; #: p,0.05 or smaller
between restrictive and COPD group.
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As expected, the restrictive patients had a high ratio of FEV1/
functional vital capacity (0.80) and the COPD patients had a
low ratio (0.31) (table 1). All participants were nonsmokers,
with the exception of one scoliotic and one COPD patient; all
the COPD patients had been smokers, as had three other
scoliotic patients and seven of the controls.
Quadriceps force measurement
Quadriceps strength differed significantly between groups
judged by the Kruskal–Wallis test when assessed using either
twitch force (p50.03) or maximal voluntary contraction (MVC;
p50.05) (fig. 1). Direct group comparisons showed that the
scoliotic patients were not statistically different from the COPD
group (table 1), but quadriceps strength was also reduced in
both scoliosis and COPD patients compared with controls
judged by MVC (p50.02 and p50.04, respectively) and, in the
case of restrictive patients, by TwQ (p50.013).
Muscle biological analyses
Results corresponding to MyHC isoform expression, oxidative
and redox balance are shown in table 2. Analysis of MyHCs
showed significant differences in the proportions of Type IIa
(p50.011), Type IIx (p50.03) and Type I (p50.001) myosin,
explained by a significant difference in the proportions of Type
I and IIa myosins between healthy subjects and COPD patients
(p50.009 and p50.0009, respectively) and by significant
differences between the scoliosis patients and controls (Type
I myosin p50.028, Type IIx p50.01). Overall, the scoliosis
group had a similar MyHC Type I profile to the COPD group
(fig. 2).
The oxidative stress markers malondialdehyde (MDA)–protein
adducts (figs 3 and 4), protein tyrosine nitration (figs 3 and 5)
and protein carbonylation differed significantly between
groups (p50.001, p50.001 and p50.05, respectively). These
differences were explained by a significant increase in the
quadriceps of scoliosis patients in MDA–protein adducts
(p50.002), protein tyrosine nitration (p50.001) and protein
carbonylation (p50.04). Statistically significant increases in
two of these variables were also observed in COPD patients
(MDA–protein adducts and protein tyrosine nitration, p50.002
and p50.008, respectively). The antioxidant mechanism man-
ganese superoxide dismutase but not catalase differed between
the three groups (table 2) and was increased in scoliotic
patients compared with COPD patients (p50.01).
Indices of oxidative stress were compared with physiological
data. No significant responses were observed, except a modest
negative relationship observed between quadriceps strength
measured as maximal voluntary contraction force and protein
tyrosine nitration (r5-0.46, p50.027).
DISCUSSION
The main finding of the present study is that patients with very
severe scoliosis display marked quadriceps weakness with a
reduction in exercise performance, judged by the 6MWT, to
approximately two-thirds of expected values. In addition to a
comparable degree of weakness, we observed, based on











































































FIGURE 1. Quadriceps strength in the three patient groups measured as
a) maximal voluntary contraction (MVC) force and b) unpotentiated quadriceps
twitch tension (TwQ). Quadriceps strength was reduced in both scoliosis and
chronic obstructive pulmonary disease (COPD) patients compared with controls
judged by MVC (p50.02 and p50.04, respectively) and, in the case of restrictive
patients, by TwQ (p50.013).







MyHC I % 47.7 (9.3) 35.3 (18.5)*,# 22.1 (16.3)*
MyHC IIA % 37.0 (3.5) 37.4 (12.8)# 50.8 (10.0)*
MyHC IIX % 11.3 (13.0) 26.3 (15.5)* 24.8 (13.4)
Total protein carbonylation 3.82 (1.14) 5.71 (2.71)* 4.08 (0.55)
MDA–protein adducts 0.46 (0.22) 1.02 (2.63)* 1.35 (0.58)*
Protein tyrosine nitration 0.24 (0.06) 0.76 (0.51)* 0.48 (0.30)*
Mn-SOD 0.70 (0.21) 0.96 (0.351)# 0.50 (0.165)
Catalase 1.32 (0.49) 1.54 (0.45) 1.34 (0.24)
Data are presented as median (interquartile range). Optical densities of the
oxidative stress markers in all cases were expressed as the ratio of the optical
densities of the specific antigen to those of glyceraldehyde-3-phosphate
dehydrogenase. The number of subjects for which biopsy data are available
may be obtained by examination of figures 2 and 3. COPD: chronic obstructive
pulmonary disease; MyHC: myosin heavy-chain isoform; MDA: malondialde-
hyde; Mn-SOD: manganese superoxide dismutase. *: p,0.05 or smaller
between patient group and control group; #: p,0.05 or smaller between
restrictive and COPD groups.
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patients and COPD patients; both groups had a reduction in
Type I myosin and evidence of oxidative stress suggesting a
common aetiological mechanism.
Critique of the method
To some extent, the present study is exploratory in nature and
therefore has some limitations. Some investigators have hypothe-
sised that COPD is a specific inflammatory disorder triggered
and modulated by tobacco smoking and that the quadriceps
weakness follows downstream from this inflammation (e.g. [18]).
If that were the case, then quadriceps weakness would not, of
necessity, be present in noninflammatory respiratory conditions
such as scoliosis. Although our data, in this context, argue against
an inflammatory aetiology to peripheral muscle weakness in
COPD, we acknowledge that blood markers of inflammation,
such as interleukin (IL)-6, IL-8 or tumour necrosis factor-a, were
not measured in the present study. Interestingly, our consortium
[19] and others [20] have recently demonstrated that these
inflammatory markers are in any case under- rather than over-
represented in the limb muscle of patients with COPD.
Considering patients with COPD and healthy adults, our study
appears small. However, patients with severe scoliosis who are
naı̈ve to noninvasive ventilation are relatively uncommon; in
fact, we were unable to find previous studies in the literature
of patients with incipient respiratory failure with this condi-
tion. We might have enlarged our cohort by including, for
example, patients with pulmonary fibrosis but we elected to
confine the restrictive group to those with an extrapulmonary
and non-neurological cause for respiratory failure in order to
attain data that were as ‘‘clean’’ as possible.
A further limitation of our study is that measures of muscle
bulk (for example, by mid-thigh computed tomography cross-
















































































































FIGURE 2. Myosin heavy-chain (MyHC) expression in the following three
groups is shown: a) Type 1; b) Type IIa; and c) Type IIx. Scoliosis patients differed
from controls in Type I MyHC isoform expression, p50.028 and Type IIx p50.01.
Chronic obstructive pulmonary disease (COPD) patients differed from controls in










































































FIGURE 3. a) Protein tyrosine nitration and b) malondialdehyde (MDA)–protein
adducts in all three groups. In scoliosis patients, MDA–protein adducts (p50.002)
and protein tyrosine nitration (p50.001) were both increased. These variables were
also increased in chronic obstructive pulmonary disease (COPD) patients (p50.002
and p50.008, respectively) compared to control subjects.
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assumed that weakness is synonymous with atrophy, although
most data, including a recent study from our group using
ultrasound [21], suggest that muscle bulk is the primary
determinant of strength [22]. Unfortunately, we did not have
6MWT data on our healthy control subjects; however, the
expected 6MWT distance for our control group would be
574 m [23]; therefore, both patient groups may be considered
to have, as expected, a substantial and clinically relevant
reduction in exercise capacity.
Significance of the findings
Our data demonstrate severe skeletal muscle weakness in
patients with extrapulmonary restrictive lung disease, accom-
panied by a change in MyHC isoform expression. Although
not directly measured, we assume weakness to be associated
with muscle wasting, i.e. loss of muscle bulk [21]. Few data on
this topic exist, although quadriceps weakness was also
observed in the few restrictive patients who participated in a
previous study investigating the effect of noninvasive mechan-
ical ventilation [24]. In addition, if they complete the course,
pulmonary rehabilitation is effective for such patients [3],
consistent with our finding that quadriceps weakness is
present.
The Barcelona group [5] and other investigators [25, 26] have
already argued that oxidative and nitrosative stress are
increased in the muscles of patients with COPD. Indeed,
oxidative stress has been proposed as one of the most
important mechanisms involved in the aetiology of peripheral
muscle dysfunction in COPD. In the current study, we again
observed that lower limb muscles of patients with COPD
undergo severe protein carbonylation and nitration. However,
showing similar findings in the vastus lateralis of patients with
scoliosis is an important development. Since these patients also
had quadriceps weakness, our data suggest that both oxidative
and nitrosative stress were also involved in the peripheral
muscle dysfunction of the scoliosis patients, although it is
acknowledged that our data do not demonstrate a causal role.
Interestingly, when considering the entire dataset, a weak
inverse relationship was observed between increasing protein
tyrosine nitration and increasing muscle weakness (data not
shown). MONTES DE OCA et al. [27] have recently reported
evidence of increased nitric oxide end-products in smokers,
but this cannot explain our observations in patients with
restrictive disease as they were, in nine out of 10 instances,
nonsmokers.
We believe the present study to be the first in which
quadriceps biopsy has been undertaken in patients with
Type II respiratory failure due to scoliosis; interestingly,
however, quadriceps biopsy of patients with scoliosis who
were not in respiratory failure was undertaken by MAFFULLI
[28], who found ‘‘a mild dominance’’ of Type I fibres, in
contrast with the current results. In the study by MAFFULLI [28],
patients were referred for spinal surgery rather than because of
suspected Type II respiratory failure and therefore disease
severity or age may explain this discrepancy. A recent meta-
analysis [29] has confirmed frequent prior observations [30–32]
that Type II fibres predominate in patients with advanced
COPD, an observation repeated in the present study. Our data
show that, in patients with scoliosis, with a degree of weakness
and respiratory impairment which equalled or exceeded that
seen in patients with COPD myosin shifts in MyHC isoform
expression also occur. Overall, the pattern in scoliosis patients
resembled COPD patients, in that Type I MyHC isoform
expression was reduced, but we note that the magnitude of the
reduction was less than in COPD patients and that in scoliotics
the ‘‘beneficiary’’ was Type IIx MyHC isoform expression,
whereas in COPD, MyHC IIa was increased. The reason for
this discrepancy is unclear and not clarified by the present
data, but since MyHCIIx is viewed by some investigators as an
adaptive response, one could speculate that this reflects the
more profound strength loss and the longer history of
preceding disease typically seen in scoliosis.
These data suggest that factors common to scoliosis and COPD
are driving fibre-type shift. The pathophysiological mechanism
remains to be elucidated and candidate mechanisms will need
to be evaluated in future studies. One striking finding in the
present study was the reduced BMI in the scoliotic patients; it
has recently been noted elsewhere that BMI is disproportion-
ately reduced in paediatric scoliotic patients with the most
severe pulmonary restriction [33], although we acknowledge
that the patients in that study were very much younger than
our own. However, similar changes were observed in COPD











FIGURE 4. Representative examples of malondialdehyde (MDA)–protein
adducts and glyceraldehyde-3-phosphate dehydrogenase in quadriceps of control
subjects, severe scoliosis patients and chronic obstructive pulmonary disease












FIGURE 5. Representative examples of protein tyrosine nitration (total 3-
nitrotyrosine immunoreactivity) and glyceraldehyde-3-phosphate dehydrogenase in
quadriceps of control subjects, severe scoliosis patients and chronic obstructive
pulmonary (COPD) patients. Several tyrosine-nitrated proteins were detected. MW:
molecular weight.
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established that the prevalence of quadriceps weakness in
COPD exceeds that of fat-free mass depletion [34, 35].
Comparison with COPD, for which more data are available,
suggests that reduced physical activity could also be a
candidate mechanism, although this was not measured in the
present study. Fibre-type changes are clinically relevant
because they predispose, in a manner related to its severity,
to leg discomfort and low-frequency fatigue during exercise
[36]. Our data suggest that this mechanism could also be
operative in scoliotics.
Factors that our COPD patients might have been exposed to,
even though studied in a stable condition, include systemic
inflammation, drugs (including corticosteroids) used to treat
prior exacerbations, and associated comorbidities, such as
peripheral vascular disease. These factors were not system-
atically evaluated in the present cohort, although no partici-
pants were using oral steroids when biopsied, or indeed for a
minimum of 4 months beforehand. Corticosteroids are known
to be associated with muscle atrophy through a myostatin-
dependent mechanism [37] which increases expression of
atrogenes, including atrogin and muscle ring finger protein 1.
However, steroid-induced muscle atrophy usually preferen-
tially involves Type II fibres, so this, coupled with the lack of
recent exposure in our cohort, seems an unlikely mechanism. It
has already been noted that systemic inflammation was not
evaluated in the present study. Patients with COPD experience
exacerbations to a greater extent than patients with scoliosis
disease; quadriceps strength is decreased during exacerbation
[38]. Data concerning the effect of exacerbation frequency on
quadriceps strength and its relationship with loss of fat-free
mass is presently sparse [35], but only two of our COPD
patients had had exacerbations in the previous year, and none
in the preceding 3 months. Lastly, hypoxaemia, at least at rest,
seems an unlikely explanation of our findings since the median
arterial oxygen tension in scoliotic patients was 9.1 kPa.
However, we acknowledge that, like COPD patients, scoliotic
patients develop exercise-induced hypoxia [39]; this was not
measured in the present study and cannot be excluded as a
potential trigger.
In conclusion, we provide the first data documenting the
function and content of the quadriceps muscle in patients with
advanced scoliosis and compare them with both COPD
patients and healthy adults. Important similarities were
weakness of the quadriceps muscle, reduced Type I myosin
and the presence of oxidative stress, suggesting a common
aetiological mechanism in both disease groups.
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